Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Galectin Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Galectin Therapeutics Inc.’s stock price such as:

• Galectin Therapeutics Inc.’s current stock price and volume
• Why Galectin Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for GALT from analysts
• GALT’s stock price momentum as measured by its relative strength

About Galectin Therapeutics Inc. (GALT)

Before we jump into Galectin Therapeutics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Want to learn more about Galectin Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Galectin Therapeutics Inc..

Galectin Therapeutics Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Galectin Therapeutics Inc.’s stock price was $4.610.

Galectin Therapeutics Inc. is up 5.98% from its previous closing price of $4.350.

During the last market session, Galectin Therapeutics Inc.’s stock traded between $4.330 and $4.720. Currently, there are approximately 65.88 million shares outstanding for Galectin Therapeutics Inc..

Galectin Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Galectin Therapeutics Inc. Stock Price History

Galectin Therapeutics Inc.’s (GALT) price is currently up 16.71% so far this month.

During the month of September, Galectin Therapeutics Inc.’s stock price has reached a high of $4.720 and a low of $3.910.

Over the last year, Galectin Therapeutics Inc. has hit prices as high as $7.130 and as low as $2.025. Year to date, Galectin Therapeutics Inc.’s stock is up 10.82%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Galectin Therapeutics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were analysts who downgraded Galectin Therapeutics Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Galectin Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Galectin Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Galectin Therapeutics Inc. (GALT) by visiting AAII Stock Evaluator.

Relative Price Strength of Galectin Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Galectin Therapeutics Inc. has a weighted four-quarter relative price strength of 23.51%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Galectin Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Galectin Therapeutics Inc. Stock Price: Bottom Line

As of September 4, 2026, Galectin Therapeutics Inc.’s stock price is $4.610, which is up 5.98% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Galectin Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.